Moleculin Biotech vs SELLAS Life Sciences
MBRX and SLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBRX and SLS compare
SELLAS Life Sciences is the larger company, worth 11 times as much as Moleculin Biotech ($1.5B against $139M).
SELLAS Life Sciences scores higher on the StockData Score (7 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBRX | SLS |
|---|---|---|
| Size and price | ||
| Market cap | $139M | $1.5B |
| Share price | $7.14 | $7.47 |
| Change, 1 year | −96.9% | 412% |
| Change, 5 years | −100.0% | 6.1% |
| Beta (5Y) | −1.16 | 0.65 |
| Employees | 150K | 13 |
| StockData Score | ||
| Total score | 4 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 12.0× | 11.0× (better) |
| Profitability | ||
| Return on equity | −524% | −39.6% (better) |
| Return on invested capital | – | −85609% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.94 | 18.83 (better) |
| Altman Z-score | −10.81 | 114.64 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.05% | 36.5% |
| Held by insiders | 20.2% | 1.8% |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 0.35% | 28.8% |
Go deeper
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
- SLS stock overview
- SLS income statement
- SLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.